You are here: / Discovery

The HSP90 Inhibitor, AT13387, is Effective Against Imatinib-Sensitve and -Resistant Gastrointestinal Stromal Tumours

/in ,

Smyth et al.. “The HSP90 Inhibitor, AT13387, is Effective Against Imatinib-Sensitve and -Resistant Gastrointestinal Stromal Tumours.” Mol Cancer Ther 2012;11:1799-1808 .

Alessandri et al. “Induction of Eosinophil Apoptosis by the Cyclin-Dependent Kinase Inhibitor AT7519 Promotes the Resolution of Eosinophil-Dominant Allergic Inflammation.” PLoS ONE 6, no. 9 2011: e25683. DOI: 10.1371/journal.pone.0025683.

/in ,

Alessandri et al. “Induction of Eosinophil Apoptosis by the Cyclin-Dependent Kinase Inhibitor AT7519 Promotes the Resolution of Eosinophil-Dominant Allergic Inflammation.” PLoS ONE 6, no. 9 2011: e25683. DOI: 10.1371/journal.pone.0025683.

Arkenau et al. “A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.” Annals of Oncology 2011. DOI: 10.1093/annonc/mdr451.

/in ,

Arkenau et al. “A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.” Annals of Oncology 2011. DOI: 10.1093/annonc/mdr451.

Brito et al. “Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.” Leukemia Research 35, no. 9 2011: 1233-1240. DOI: 10.1016/j.leukres.2011.01.011.

/in ,

Brito et al. “Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma.” Leukemia Research 35, no. 9 2011: 1233-1240. DOI: 10.1016/j.leukres.2011.01.011.

Heightman, Tom D. “Therapeutic prospects for epigenetic modulation.” Expert Opinion on Therapeutic Targets 15, no. 6 2011: 729-740. DOI: 10.1517/14728222.2011.561786.

/in ,

Heightman, Tom D. “Therapeutic prospects for epigenetic modulation.” Expert Opinion on Therapeutic Targets 15, no. 6 2011: 729-740. DOI: 10.1517/14728222.2011.561786.

Mahadevan et al. “A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.” Annals of Oncology 22, no. 9 2011: 2137-2143. DOI: 10.1093/annonc/mdq734.

/in ,

Mahadevan et al. “A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.” Annals of Oncology 22, no. 9 2011: 2137-2143. DOI: 10.1093/annonc/mdq734.